Focused On-demand Library for Uridine-cytidine kinase 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9HA47

UPID:
UCK1_HUMAN

ALTERNATIVE NAMES:
Cytidine monophosphokinase 1; Uridine monophosphokinase 1

ALTERNATIVE UPACC:
Q9HA47; Q5JT09; Q5JT10; Q5JT12; Q5JT13; Q6IA74; Q96BJ0

BACKGROUND:
The enzyme Uridine-cytidine kinase 1, with alternative names Cytidine monophosphokinase 1 and Uridine monophosphokinase 1, is pivotal in the phosphorylation of uridine and cytidine, crucial steps in nucleotide biosynthesis. It does not act on deoxyribonucleosides or purine ribonucleosides but can use ATP or GTP as phosphate sources. Its capacity to phosphorylate various cytidine and uridine nucleoside analogs underlines its potential utility in therapeutic drug development.

THERAPEUTIC SIGNIFICANCE:
The exploration of Uridine-cytidine kinase 1's function offers a fertile ground for uncovering novel therapeutic approaches. Given its role in nucleoside metabolism and the ability to act on nucleoside analogs, this protein is a key target in the design of new treatments for viral infections and cancer, highlighting its therapeutic significance.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8474 of 8789